News Image

Uncovering Noteworthy Technical Analysis Findings for ELI LILLY & CO (NYSE:LLY).

By Mill Chart

Last update: Nov 21, 2023

Our stock screener has detected a potential breakout setup on ELI LILLY & CO (NYSE:LLY). This breakout pattern is observed when a stock consolidates following a strong upward movement. It's important to note that this pattern is based on technical analysis, and the actual breakout outcome is uncertain. However, it might be worth keeping an eye on NYSE:LLY.

LLY Daily chart on 2023-11-21

Technical Analysis Observations

ChartMill employs a sophisticated system to assign a Technical Rating to every stock in its analysis. This rating, which ranges from 0 to 10, is determined by carefully assessing multiple technical indicators and properties.

Taking everything into account, LLY scores 10 out of 10 in our technical rating. This is due to a consistent performance in both the short and longer term time frames. Also compared to the overall market, LLY is showing a nice and steady performance.

  • The long and short term trends are both positive. This is looking good!
  • When comparing the yearly performance of all stocks, we notice that LLY is one of the better performing stocks in the market, outperforming 94% of all stocks. We also observe that the gains produced by LLY over the past year are nicely spread over this period.
  • LLY is one of the better performing stocks in the Pharmaceuticals industry, it outperforms 94% of 206 stocks in the same industry.
  • LLY is currently trading near its 52 week high, which is a good sign. The S&P500 Index however is also trading near new highs, which makes the performance in line with the market.
  • In the last month LLY has a been trading in the 547.61 - 625.87 range, which is quite wide. It is currently trading in the middle of this range, so some resistance may be found above.

Our latest full technical report of LLY contains the most current technical analsysis.

Why is NYSE:LLY a setup?

ChartMill takes into account not only the Technical Rating but also assigns a Setup Rating to each stock. This rating, on a scale of 0 to 10, reflects the degree of consolidation observed based on short-term technical indicators. Currently, NYSE:LLY exhibits a 8 setup rating, indicating its consolidation status in recent days and weeks.

Besides having an excellent technical rating, LLY also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. A pullback is taking place, which may present a nice opportunity for an entry. There is a support zone below the current price at 586.14, a Stop Loss order could be placed below this zone.

How to trade NYSE:LLY?

To potentially initiate a trade, it is common practice to wait for the stock to break out of the consolidation zone. This breakout signifies a potential upward movement, and traders may enter the stock at that point. Conversely, if the stock falls back below the consolidation zone, it may be sold at a loss.

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents technical observations generated by automated analysis but does not guarantee any trading outcomes. Always trade responsibly and make independent judgments.

Our Breakout screener lists more breakout setups and is updated daily.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

ELI LILLY & CO

NYSE:LLY (4/24/2024, 1:05:45 PM)

735.16

-10.53 (-1.41%)

LLY News

News Image8 hours ago - The Motley FoolMeet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market

Lilly recently announced news that could solve a big problem.

News Image8 hours ago - InvestorPlace3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.

News Image9 hours ago - The Motley FoolMissed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Good news could be just around the corner for two drugmakers not named Novo Nordisk.

News Imagea day ago - Zacks Investment ResearchEli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News Imagea day ago - The Motley FoolBetter Buy: Pfizer vs. Viking Therapeutics

These two pharma stocks have followed distinct paths of late. Which is the better investment?

News Imagea day ago - InvestorPlace3 Stocks With the Potential to Surpass Analyst Expectations for 2024

These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.

News Image2 days ago - Zacks Investment ResearchEli Lilly (LLY) Advances But Underperforms Market: Key Facts

Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.

News Image2 days ago - InvestorPlace7 High-Flying Stocks That Are Majorly Overdue for a Pullback

After performing strongly since the start of the year, it's time to sell these stocks due for a pullback before they reverse course.

News Image2 days ago - BloombergTikTok’s Crackdown on Ozempic Influencers Threatens Weight-Loss Drug Hype Machine

Creators say the rules are unfair and harmful to their businesses

News Image2 days ago - TheNewswire.com6 Stocks Positioned to Soar as Investors Focus on MASH

Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was expanded to treat obesity, an even bigger market. JP Morgan analyst Richard Vosser estimated the global obesity drug market will reach $71 billion by 2032.

News Image3 days ago - BloombergAfrica’s Biggest Drugmaker Can Help Ease Obesity Medicine Supply Crunch

Africa’s biggest drugmaker could potentially help ease a growing supply crunch for the world’s hottest obesity medications.

News Image4 days ago - The Motley FoolMissed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

Altimmune has a modest market cap but an incredibly promising GLP-1 drug.

LLY Links
Follow us for more